Published On : August 2026
Every organisation developing an allogeneic cell therapy faces the same early question: whether to build manufacturing capability or to buy it from someone else.
That decision structures the global allogeneic cell therapy market more than any other single factor, because it determines who the customers are.
A developer that builds a facility removes itself from the addressable market for years and becomes a competitor for capacity rather than a buyer of it.
A developer that outsources becomes a long-term customer, since programmes rarely move between manufacturing partners once established.
That asymmetry is why manufacturing organisations follow the build or buy decisions of developers as closely as they follow programme announcements.
The decision itself turns on capital availability, programme stage, internal capability already held and how quickly a developer needs to move.
Capital is usually the binding constraint, since a compliant facility carries a cost that most development organisations cannot justify against a single programme.
Programme stage matters because early work is cheaper to outsource and later work is more expensive to move.
Existing capability matters because an organisation with partial capability faces a different question from one starting with none.
Speed matters because building takes years and buying does not, which is decisive for organisations working against a funding timetable.
This report tracks three manufacturing models and two manufacturing scales, together with nine service categories bought alongside manufacturing itself.
Nothing on this page describes how any manufacturing process is carried out, and no statement is made about any facility, process or programme.
The subject throughout is how manufacturing is sourced commercially rather than how it is performed technically.
In-house manufacturing describes a developer producing therapy material in its own facility rather than commissioning another organisation to do so.
This report tracks it as one of three manufacturing model categories and describes nothing about how any such facility operates.
The category is dominated by larger organisations, since the capital required is difficult to justify at smaller scale.
For those organisations, building removes an external dependency and gives direct control over scheduling, which is commercially significant at later stages.
It also converts a variable cost into a fixed one, which is favourable at volume and unfavourable below it.
That crossover point is the whole of the economic argument, and it sits at a volume most development organisations never reach.
Facilities also take years to build and qualify, which means the decision is made against an expected pipeline rather than a current one.
Where that pipeline does not materialise, the facility becomes an underused fixed cost that is difficult to unwind.
Several organisations have subsequently offered spare capacity to others, which is one route by which new manufacturing supply enters this market.
Personnel are the second constraint and are frequently underestimated, since experienced manufacturing and quality staff are scarce across the whole market.
A facility without staff is not capacity, and recruitment timetables have delayed more than one internal manufacturing programme.
Commercially, the in-house category matters to manufacturing organisations mainly as a measure of how much demand is leaving the addressable market.
It matters to buyers as a benchmark, since the cost of building internally is what an outsourced arrangement is ultimately compared against.
Contract manufacturing describes a developer commissioning another organisation to produce therapy material on its behalf.
It is the largest manufacturing model category in this report, and it is the arrangement most development organisations use.
The organisations serving this category vary widely, and the platforms each manufacturing arrangement supports differ considerably between them.
The commercial logic is straightforward: a developer converts a large capital commitment into a programme cost it can fund alongside development itself.
That conversion is what allows smaller organisations to advance programmes at all, and it is why this category dominates the market.
Contract arrangements typically begin with process development work before any manufacturing takes place.
That early engagement matters commercially because it establishes a relationship that later manufacturing work usually follows.
Moving a programme to a different organisation after process development is costly and slow, which makes early positions unusually durable.
That durability is the single most important commercial characteristic of this category and shapes how manufacturing organisations compete.
It also means competition concentrates at the point of first engagement rather than being contested at every stage.
Capacity commitment across stages is a common point of negotiation, since developers want assurance that capacity will be available later.
Manufacturing organisations balance that against the risk of reserving capacity for programmes that may not advance.
That tension is the ordinary commercial substance of this category and appears in most agreements in some form.
Hybrid manufacturing describes an arrangement where a developer performs some manufacturing activity internally and commissions the rest externally.
It is the fastest-growing manufacturing model category in this report, and its growth is one of the more commercially significant trends in the market.
The arrangement typically arises when an organisation has built partial capability but not enough to cover a full programme.
It also arises when a developer wants internal capability for early work while retaining external capacity for later scale.
Commercially, hybrid arrangements are important because they keep an organisation in the addressable market rather than removing it.
A developer that builds entirely leaves; one that builds partially continues to buy, which sustains demand that would otherwise disappear.
For manufacturing organisations, hybrid customers are demanding but valuable, since they understand manufacturing and buy specific capability rather than a whole service.
That specificity favours organisations with genuine depth in particular activities over those offering broad general capability.
Hybrid arrangements also require more coordination than fully outsourced ones, since activity moves between facilities during a programme.
Technology transfer is therefore central to the category and is one of the nine service types this report tracks separately.
The growth of this category reflects a market maturing, where developers make component decisions rather than a single build or buy choice.
That maturation favours manufacturing organisations positioned as specialist providers rather than as full-service alternatives to building.
It is a meaningful shift in how this market competes and is not yet fully reflected in how capability is presented.
This report separates manufacturing into two scale categories: clinical scale and commercial scale.
Clinical scale describes manufacturing supporting programmes still in development, and commercial scale describes manufacturing supporting products already on the market.
Both are used here strictly as segmentation labels, with nothing stated about any programme, product or approval.
Clinical scale accounts for the majority of current manufacturing demand, which reflects where the bulk of allogeneic development activity currently sits.
Commercial scale is the faster-growing category but grows from a much smaller base and remains a minority of total demand.
The commercial difference between them is larger than the names suggest and is frequently underestimated by developers.
Clinical scale work is smaller in volume, more variable in specification and more tolerant of change between runs.
Commercial scale work is larger, more repeatable and far less tolerant of change, which places different demands on a facility.
Few manufacturing organisations are equally strong at both, and the transition between them is where many programmes encounter difficulty.
That transition is also where manufacturing partners are most often changed, despite the cost of doing so.
For manufacturing organisations, capability across the transition is therefore a genuine commercial differentiator rather than a marketing claim.
For buyers, it is worth establishing at the outset rather than discovering when a programme is already advancing.
Capacity positioned for that transition is identified in this report as one of the clearer opportunities in the market.
Nine service categories appear in this report alongside manufacturing itself, and together they account for a substantial share of what developers actually buy.
Which of them a programme buys depends heavily on the organisations that commission each arrangement, since capability held internally varies widely by buyer type.
Cell processing and manufacturing form the core, with analytical testing, quality assurance and regulatory consulting sold around them.
Cryopreservation and logistics form a distinct group concerned with storage and movement rather than production.
Technology transfer describes moving a process between facilities and is central to hybrid arrangements and to any change of manufacturing partner.
Commercial manufacturing support completes the set and concerns the transition from clinical to commercial supply.
Analytical testing is the service most frequently bought separately, and demand for it has grown faster than manufacturing demand itself.
That growth reflects developers buying specialist capability rather than building analytical functions internally.
Quality assurance and regulatory consulting follow a similar pattern and are frequently bought from organisations that do no manufacturing at all.
Logistics is a distinct commercial activity in this market and is more consequential than in most manufacturing sectors.
Cryopreservation sits alongside it and is likewise bought as a specialist service rather than performed internally by most developers.
For manufacturing organisations, service breadth widens the commercial relationship well beyond manufacturing volume alone.
This report identifies service portfolio gaps as one of the clearer opportunities in the market, and analytical and quality services are where those gaps are widest.
It describes a developer commissioning another organisation to produce therapy material on its behalf. It is the largest manufacturing model category in this report and the arrangement most development organisations use.
An arrangement where a developer performs some manufacturing internally and commissions the rest externally. It is the fastest-growing manufacturing model category and keeps developers in the market as buyers of specific capability.
Clinical scale supports programmes still in development; commercial scale supports products already on the market. The two place materially different demands on a facility, and few organisations are equally strong at both.
Nine categories are tracked: cell processing, manufacturing, analytical testing, quality assurance, regulatory consulting, cryopreservation, logistics, technology transfer and commercial manufacturing support.